tbuckley/cabot-search huggingface dataset:
Conventional Versus Compression-Only Versus No-Bystander Cardiopulmonary Resuscitation for Pediatric Out-of-Hospital Cardiac Arrest
Authors: Tatsuma Fukuda, Naoko Ohashi-Fukuda, Hiroaki Kobayashi, Masataka Gunshin, Toshiki Sera, Yutaka Kondo, Naoki Yahagi
Journal: Circulation (2016)

Background: Conventional cardiopulmonary resuscitation (CPR) (chest compression and rescue breathing) has been recommended for pediatric out-of-hospital cardiac arrest (OHCA) because of the asphyxial nature of the majority of pediatric cardiac arrest events. However, the clinical effectiveness of additional rescue breathing (conventional CPR) compared with compression-only CPR in children is uncertain. Methods: This nationwide population-based study of pediatric OHCA patients was based on data from the All-Japan Utstein Registry. We included all pediatric patients who experienced OHCA in Japan from January 1, 2011, to December 31, 2012. The primary outcome was a favorable neurological state 1 month after OHCA defined as a Glasgow-Pittsburgh Cerebral Performance Category score of 1 to 2 (corresponding to a Pediatric Cerebral Performance Category score of 1–3). Outcomes were compared with logistic regression with uni- and multivariable modeling in the overall cohort and for a propensity-matched subset of patients. Results: A total of 2157 patients were included; 417 received conventional CPR, 733 received compression-only CPR, and 1007 did not receive any bystander CPR. Among these patients, 213 (9.9%) survived with a favorable neurological status 1 month after OHCA, including 108/417 (25.9%) for conventional, 68/733 (9.3%) for compression-only, and 37/1007 (3.7%) for no-bystander CPR. In unadjusted analyses, conventional CPR was superior to compression-only CPR in neurologically favorable survival (odds ratio [OR] 3.42, 95% confidence interval [CI] 2.45–4.76; P &lt;0.0001), with a trend favoring conventional CPR that was no longer statistically significant after multivariable adjustment (OR adjusted 1.52, 95% CI 0.93–2.49), and with further attenuation of the difference in a propensity-matched subset (OR 1.20, 95% CI 0.81–1.77). Both conventional and compression-only CPR were associated with higher odds for neurologically favorable survival compared with no-bystander CPR (OR adjusted 5.01, 95% CI 2.98–8.57, and OR adjusted 3.29, 95% CI 1.93–5.71), respectively. Conclusions: In this population-based study of pediatric OHCA in Japan, both conventional and compression-only CPR were associated with superior outcomes compared with no-bystander CPR. Unadjusted outcomes with conventional CPR were superior to compression-only CPR, with the magnitude of difference attenuated and no longer statistically significant after statistical adjustments. These findings support randomized clinical trials comparing conventional versus compression-only CPR in children, with conventional CPR preferred until such controlled comparative data are available, and either method preferred over no-bystander CPR.
FLT3-ITD-Associated Accumulation of Dendritic Cell Precursors, Depletion of Mature Dendritic Cells and Abnormal Cytokine Production in Acute Myeloid Leukemia: Analyses At Diagnosis, Remission and Relapse
Authors: Renata Stripecke, Mareike Rickmann, Bala Sai Sundarasetty, Arnold Ganser
Journal: Blood (2011)
Randomised comparison of needle aspiration and chest tube drainage in spontaneous pneumothorax
Authors: A. Thelle, M. Gjerdevik, M. SueChu, O. M. Hagen, P. Bakke
Journal: European Respiratory Journal (2017)

Guidelines on spontaneous pneumothorax are contradictory as to intervention between needle aspiration (NA) and chest tube drainage (CTD). Studies show poor adherence to guidelines. Three Norwegian hospitals included patients with primary (PSP) and secondary (SSP) spontaneous pneumothorax. Patients underwent NA or CTD as the primary intervention. The main outcome was duration of hospital stay. Secondary outcomes were immediate- and 1-week success rates and complications. 127 patients were included, including 48 patients with SSP. 65 patients underwent NA, 63 patients CTD. Median (interquartile range) hospital stay was significantly shorter for NA: 2.4 days (1.2–4.7 days), compared with CTD: 4.6 days (2.3–7.8 days) (p&lt;0.001). The corresponding figures for the SSP subgroup were 2.54 days (1.17–7.79 days) compared with 5.53 days (3.65–9.21 days) (p=0.049) for NA and CTD, respectively. Immediate success rates were 69% for NA compared with 32% for CTD (p&lt;0.001). The positive effect of NA remained significant in sub-analyses for SSP. There was no significant difference in 1-week success rates. Complications occurred only during the CTD-treatment. Our study shows shorter hospital stay and higher immediate success rates for NA compared with CTD. Subgroup analyses also show clear benefits for NA for both PSP and SSP.
AB0746 High Prevalence of Cardiovascular Comorbidity in Patients with Psoriatic Arthritis and Moderate-To-Severy Plaque Psoriasis: A Retrospective Dermatological Clinic-Based Study
Authors: N. Batkaeva, T. Korotaeva, E. Batkaev
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> An association between inflammation, psoriasis (PsO), psoriatic arthritis (PsA) and increased cardiovascular comorbidity has still limited data. <h3>Objectives</h3> to evaluate the prevalence of cardiovascular comorbidity in patients (pts) with PsA and PsO without arthritis in the dermatological hospital cohort. <h3>Methods</h3> 592 pts (Male-348/Female-244) with moderate-to-severy plaque PsO, mean age 49.2±0.6 years, mean PsO duration 11.8±0.6 were included. PsO and PsA pts with cardiovascular disease (CVD), including coronary heart disease (CHD), arterial hypertension, (AH), atherosclerosis and cerebrovascular accident (CVA) were identify in the hospital Database reporting and coding by International Statistical Classification of Disease and Related Health Problems (ICD-10) between 2010 - 2011 years. M±m, t-test, (%) were calculated. All p&lt;0.05 were considered to indicate statistical significance. <h3>Results</h3> 220 out of 592 pts (37.2%) had PsA and 372 out of 592 pts (62.8%) had PsO alone. PsA pts were older then PsO pts – 53.3±0.9 and 46.9±0.9 (p&lt;0.001). In PsA pts CVD coding as I 00 – I 99 were found in significantly more cases than in PsO pts – in 155 out of 220 pts (70.5%)/in 200 out of 372 pts (53.5%) accordingly (p&lt;0.05). In PsA pts AH coding as I 10 - I 15 was found in significantly more cases than in PsO pts - in 138 out of 220 pts (62.7%) and in 178 out of 372 pts (47.9%) accordingly (p&lt;0.001). In PsA pts CVA coding as I 65 – I 66 found significantly often than in PsO pts - in 48 out of 220 pts (22%) and in 57 out of 372 pts (15.3%) accordingly (p&lt;0.05). CHD and Atherosclerosis coding as I 70 were registered significantly often in PsA pts compared to PsO pts – in 40 out of 220 pts (18%) and in 35 out of 372 pts (9.3%) accordingly (p&lt;0.001). <h3>Conclusions</h3> Cardiovascular comorbidity is common for PsA and PsO without arthritis pts. High frequency of CVD in PsA than PsO could be due to share inflammation pathways with atherosclerosis and age. Screening and accurate management of CVD risk factors in both diseases are needed. <h3>Disclosure of Interest</h3> None declared
Efflux of the Tyrosine Kinase Inhibitors Imatinib and Nilotinib (AMN107) Is Mediated by ABCB1 (MDR1)-Type P-Glycoprotein.
Authors: Marius Dohse, Robert W. Robey, Cornelia Brendel, Susan Bates, Andreas Neubauer, Christian Scharenberg
Journal: Blood (2006)
Activating Mutations of the FMS-Like Tyrosine Kinase-3 (FLT3) At Complete Response and Relapse in Patients with Acute Myeloid Leukemia,
Authors: Aziz Nazha, Jorge E. Cortes, Stefan Faderl, Sherry Pierce, Guillermo Garcia-Manero, Susan O'Brien, Alessandra Ferrajoli, Tapan Kadia, Gautam Borthakur, Rajyalakshmi Luthra, Hagop M. Kantarjian, Farhad Ravandi
Journal: Blood (2011)
Alkylator-Induced DNA Damage Response in Multiple Myeloma (MM) Cells Is Amplified by Histone Deacetylase (HDAC) Inhibition, Resulting in Significant Synergism in Cell Death
Authors: Choon Kee Lee, Shuiliang Wang, Xiaoping Huang, John Ryder, Peter Ordentlich, Bolin Liu
Journal: Blood (2008)
FRI0073 First Report of Symptoms Using The Symptoms in Persons at Risk of Rheumatoid Arthritis (SPARRA) Questionnaire: Table 1.
Authors: M.V. Beers-Tas, L.V. Tuyl, K. Raza, R. Stack, A. Finck, D. Courvoisier, A. Catrina, A. Hensvold, E. Mosor, T. Stamm, D.V. Schaardenburg
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Persons at risk of rheumatoid arthritis (RA) may experience a variety of symptoms<sup>1,2</sup>. However, information on location, timing, severity and predictive value of these symptoms is largely lacking. The Symptoms in Persons At Risk of Rheumatoid Arthritis (SPARRA) questionnaire has been developed with support of EULAR to provide more insight into these symptoms. <h3>Objectives</h3> Report the symptoms and symptom complexes using the SPARRA questionnaire in an international group of arthralgia patients at risk of developing RA. <h3>Methods</h3> The SPARRA questionnaire contains questions on presence, severity, impact and location of 13 symptoms derived from a qualitative study in seropositive arthralgia patients<sup>1</sup>. The items are: joint pain or swelling, joint stiffness, burning and tingling sensations, numbness, changes in skin colour, muscle cramps, weakness, fatigue, emotional distress, concentration difficulties and sleep problems. Answers are given on an ordinal scale. If present, number of days with a symptom per month (0, 1–5, 6–15, 16–30 days), severity (none, mild, moderate and severe) and influence (no, small, moderate or high impact) were recorded. Secondly, we recorded the location of joint pain. Finally, patients were asked to describe the pattern of symptom development over time. Patients were included in the Netherlands (N=68), United Kingdom (N=16), Sweden (N=15), Austria (N=11) and Switzerland (N=21). Validation of the questionnaire is ongoing. <h3>Results</h3> Of 131 arthralgia patients included, 85 were positive for anti-citrullinated protein antibodies (ACPA), 29 were positive for rheumatoid factor only, and 17 were seronegative with clinically suspect arthralgia. Most symptoms were present in a high percentage of patients, with pain as the most often experienced symptom and change of skin color rarely reported. When a symptom was present, it was usually experienced as moderate to severe, and with moderate impact by half of the patients (Table 1). The mean presence of symptoms was similar in the ACPA positive and negative groups, however, ACPA positive patients more often had severe symptoms (mean 61% versus 54%, NS) with higher impact (48% versus 41%, NS). Joint pain was most frequently located in the fingers. The most frequently reported pattern of symptoms was "coming and going, but always present" (32%). <h3>Conclusions</h3> The first results of the SPARRA questionnaire show multiple symptoms to be present in a high percentage of persons at risk for RA. These are often experienced as severe, with a high impact. <h3>References</h3> Stack, Rheumatology 2014; van Tuyl, Musculoskel Care 2015 <h3>Disclosure of Interest</h3> None declared
Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression
Authors: Maria Parkhurst, Alena Gros, Anna Pasetto, Todd Prickett, Jessica S. Crystal, Paul Robbins, Steven A. Rosenberg
Journal: Clinical Cancer Research (2016)

Purpose: The adoptive transfer of lymphocytes genetically modified to express tumor reactive T-cell receptors (TCR) can mediate tumor regression. Some tumor-infiltrating lymphocytes (TIL) recognize somatic mutations expressed only in the patient's tumors, and evidence suggests that clinically effective TILs target tumor-specific neoantigens. Here we attempted to isolate neoantigen-reactive TCRs as a prelude to the treatment of patients with autologous T cells genetically modified to express such TCRs.Experimental Design: Mutations expressed by tumors were identified using whole-exome and RNA sequencing. Tandem minigene (TMG) constructs encoding 12-24 mutated gene products were synthesized, each encoding the mutated amino acid flanked by 12 amino acids of the normal protein sequence. TILs were cultured with autologous dendritic cells (DC) transfected with in vitro transcribed (IVT) mRNAs encoding TMGs and were evaluated for IFNγ secretion and CD137 expression. Neoantigen-reactive T cells were enriched from TILs by sorting for CD137+ CD8+ T cells and expanded in vitro Dominant TCR α and β chains were identified in the enriched populations using a combination of 5' rapid amplification of cDNA ends, deep sequencing of genomic DNA, PairSeq analysis, and single-cell RT-PCR analysis. Human PBL retrovirally transduced to express the TCRs were evaluated for recognition of relevant neoantigens.Results: We identified 27 TCRs from 6 patients that recognized 14 neoantigens expressed by autologous tumor cells.Conclusions: This strategy provides the means to generate T cells expressing neoantigen-reactive TCRs for use in future adoptive cell transfer immunotherapy trials for patients with cancer. Clin Cancer Res; 23(10); 2491-505. ©2016 AACR.
Bevacizumab Reduces VEGF Expression in Patients with Relapsed and/or Refractory Acute Myeloid Leukaemia (AML) without Clinical Antileukemic Activity.
Authors: Lejla Zahiragic, Christoph Schliemann, Ralf Bieker, Wolfgang E. Berdel, Rolf M. Mesters
Journal: Blood (2006)
Clinical Relevance of JAK2V617F Allele Burden in Primary and Post-Polycythemic/Post-Thrombocythemic Myelofibrosis
Authors: Paola Guglielmelli, Giovanni Barosi, Alessandro Pancrazzi, Giovanni Longo, Elisabetta Antonioli, Lisa Pieri, Flavia Biamonte, Vanessa Ponziani, Alessandro Rambaldi, Alberto Bosi, Tiziano Barbui, Alessandro M. Vannucchi
Journal: Blood (2008)
A Critical Role for the Bcl-2 Pathway in Notch-Mediated B Cell Apoptosis, Where Growth Arrest Is Independent of the E2A, IL-3 and p21Waf1/p27Kip1 Pathways.
Authors: Patrick A. Zweidler-McKay, Julian J. Lum, Craig B. Thompson, Warren S. Pear
Journal: Blood (2005)
Efficacy and Safety of Combined Rituximab and Ipilimumab to Treat Patients with Relapsed/Refractory CD20+ B-Cell Lymphoma
Authors: Barbara Marie Galligan, Denice Tsao-Wei, Susan Groshen, Mark Kirschabum, Robert O'Donnell, Paul R. Kaesberg, Tanya Siddiqui, Leslie Popplewell, Ailawadhi Sikander, Htut Myo, Robert Chen, John F. DiPersio, Neil D. Palmisiano, David F. Claxton, Edward M. Newman, Joseph Tuscano
Journal: Blood (2015)
Using technology to measure daily and weekly movement patterns in exercise medicine patients
Authors: John W Orchard
Journal: British Journal of Sports Medicine (2016)

One of the perceived benefits of Formula One racing is that improvements in motor vehicle technology and safety can be subsequently enjoyed by regular cars driven by members of the public. Sport and exercise medicine is on the verge of applying a similar paradigm, with important implications for safely getting the population to be more active.

BJSM readers appreciate that a ‘hot’ topic is the relationship between workloads and injuries in elite athletes.1–3 Global Positioning System technology has allowed running loads in particular to be measured in training and match situations. The headline finding of recent research is that sudden change (upwards) of workload is much more of a risk for injury than absolute workload itself.4 Having high baseline workload can be protective against injury because it ‘immunises’ against a sudden increase (a ‘spike’) in workload.5 In contrast, excessive ‘rest’ (inactivity) can sometimes be a risk factor for (and therefore even a cause of) injury because it exposes the athlete to a likely workload spike …
Comparison of Ruxolitinib , Momelotinib, and Pacritinib in the Inhibition of Immune Differentiation and Proliferation of T Cells in Myeloproliferative Neoplasm
Authors: Chi Chen, Hemant Sindhu, Ajay Kundra, Maryna Yarotska, Tony W. Cheung, Jen-Chin Wang
Journal: Blood (2015)
Long Term Significance of Response in Multiple Myeloma After Stem Cell Transplantation.
Authors: Joaquin Martínez-López, Joan Blade, M. Carmen Gomez del Castillo, Maria Victoria Mateos, Adrian Alegre, José Garcia-Laraña, Anna Sureda, Javier de la Rubia, Eulogio Conde, Rafael Martínez, Felipe de Arriba, Jose Luis Gomez Zamudio, Juan Besalduch, Rafael Cabrera, M. Cruz Biguria, Jose Maria Moraleda, J.F San Miguel, Juan José Lahuerta
Journal: Blood (2009)
Association of a TNFSF13B (BAFF) regulatory region single nucleotide polymorphism with response to rituximab in antineutrophil cytoplasmic antibody–associated vasculitis
Authors: Federico Alberici, Rona M. Smith, Mariana Fonseca, Lisa C. Willcocks, Rachel B. Jones, Julia U. Holle, Stefan Wieczorek, Thomas Neumann, Davide Martorana, Gina Gregorini, Renato A. Sinico, Annette Bruchfeld, Iva Gunnarsson, Sophie Ohlsson, Bo Baslund, Vladimir Tesar, Zdenka Hruskova, Maria C. Cid, Augusto Vaglio, Paul A. Lyons, Kenneth G.C. Smith, David R.W. Jayne
Journal: Journal of Allergy and Clinical Immunology (2016)
Dual Inhibition of Blood Coagulation Factors Xa and Iia Synergize To Reduce Thrombus Weight and Thrombin Generation in a Rabbit Arteriovenous Shunt Model of Thrombosis.
Authors: Thomas B. McClanahan, Sangita M. Baxi, Liguo Chi, Tawny Dahring, Weston R. Gould, Ted Johnson, Gary Hicks, Kathy Welch, Robert J. Leadley
Journal: Blood (2005)
Transplant Centre Experience and Patient Selection Are the Key Elements Associated with Outcome of RIC and MAC HSCT for CML.
Authors: Charles R. Crawley, Ronald Brand, Eduardo Olavarria, Theo M. de Witte, Jane F. Apperley, Dietger W. Niederwieser, Cesare Guglielmi, Per T. Ljungman, Alois Gratwohl
Journal: Blood (2007)
Support for a Possible "Vaccinal" Effect of Rituximab; Lymphoma Idiotype Specific T-Cell Responses in Follicular Lymphoma Patients Treated with Rituximab.
Authors: Shannon P. Hilchey, Ollivier Hyrien, Richard Bankert, Daniel P. Gold, Faith Young, Jonathan Friedberg, Richard I. Fisher, Steven H. Bernstein
Journal: Blood (2007)
Persistence of Cytogenetic Abnormalities at Complete Remission Is Not Prognostic for Relapse-Free or Overall Survival in Adult Patients with Acute Lymphoblastic Leukemia
Authors: Nicholas J. Short, Hagop M. Kantarjian, Elias Jabbour, Susan O'Brien, Stefan Faderl, Jan A. Burger, Rebecca Garris, Wei Qiao, Xuelin Huang, Nitin Jain, Marina Konopleva, Tapan Kadia, Naval Daver, Gautam Borthakur, Jorge E. Cortes, Farhad Ravandi
Journal: Blood (2015)
Direct and Continuous Inhibition of ADAM17 Using a Novel Selective Inhibitor Restores Functional Platelet Yield From Human Pluripotent Stem Cells
Authors: Shinji Hirata, Ryoko Jono-Ohnishi, Satoshi Nishimura, Naoya Takayama, Sou Nakamura, Hiromitsu Nakauchi, Takahiko Murata, Koji Eto
Journal: Blood (2011)
FRI0409 Subclinical Atherosclerosis in Ankylosing Spondylitis. Does It Really Exist and Which Are The Effects of Treatments? A Systematic Review
Authors: C. Prati, X. Guillot, F. Verhoeven, C. Demougeot, D. Wendling
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Objectives</h3> Accelerated atherosclerosis and increased cardiovascular morbidity and mortality have been associated with ankylosing spondylitis (AS). Noninvasive angiological methods have been developped to evaluate endothelial and vascular dysfunction which is correlated with future development of atherosclerosis. The objectives were to determinate the presence or not of a subclinical vascular dysfunction in AS and if treatments could have an effect on it. A systematic review was done. <h3>Methods</h3> Studies evaluating subclinical atherosclerosis and vascular function in AS were identified using Pubmed, (Ovid, EMBASE). Search terms included "ankylosing spondylitis" AND (endothelial OR vascular OR intima media thickness (IMT) OR Flow mediated dilatation (FMD) OR pulse wave velocity (PWV) OR atherosclerosis). This identified 353 results after limiting to French and English. The final selection identified 29 articles. <h3>Results</h3> Overall, 1529 AS patients were included representing 38 studies: 8 studies about endothelial function, 198 AS patients and 130 healthy control (HC); 20 studies about carotid IMT, 900 AS and 644 HC; 10 studies about arterial rigidity, 431 AS and 285 HC. In cross-sectional studies, 4/6 indicated endothelial dysfunction in AS versus HC, 9/18 indicated increased cIMT and 3/5 increased arterial rigidity. About ED, 3 open label studies noted positive effect of TNFα blockers and spironolactone on FMD and rosuvastatin improved FMD in a placebo controlled study after 24 weeks. TNFα blockers seems not to improve neither cIMT (2 studies) nor arterial rigidity (5 studies). Exercise alone has improved arterial rigidity in 15 patients after 12 weeks. <h3>Conclusions</h3> Whereas early and accelerated atherosclerosis is patent in AS, presence of subclinical atherosclerotic lesions is controversial in the literature especially concerning cIMT and arterial stiffness. This is reinforced by the lack of TNF blockers efficacy. Conversely it seems that endothelial dysfunction is present and reversible after treatment with TNF blockers, statin and spironolactone. These results are consistent to treat AS patients with early effective treatment to prevent the risk of CV morbidity and mortality. <h3>Disclosure of Interest</h3> None declared
NOTCH1 Signaling Defines a Leukemia Initiating Cell Population in T-Cell Acute Lymphoblastic Leukemia
Authors: Wenxue Ma, Kristen M. Smith, Alejandro Gutierrez, Heather S. Leu, Qingfei Jiang, Christina C.N. Wu, Alice Y. Shih, Angela C. Court-Recart, Anil Sadarangani, Daniel J. Goff, Ping Wei, A. Thomas Look, Catriona H.M. Jamieson
Journal: Blood (2011)
A phase II study employing Hepatic Intrarterial Irinotecan Drug-Eluiting Beads (DEBIRI) as salvatage therapy in liver metastatic colorectal cancer patients: the first South Italy experience
Authors: G. Ranieri, I. Marech, C. Altini, V. Fazio, L. Caporusso, M. Porcelli, G. Vinciarelli, F. Macina, D. de Ceglia, M. Fanelli, M. Ammendola, F. Armenise, A. Niccoli Asabella, G. Rubini, C.D. Gadaleta
Journal: Annals of Oncology (2015)
Complement System Activation after Allogeneic Bone Marrow Transplantation May Early Predict the Development of Acute Gastrointestinal GVHD.
Authors: Marie T. Rubio, Marie A. Dragon-Durey, Sébastien Jacquelin, Jacques Blouin, Natacha Maillard, David Ghez, Felipe Suarez, Richard Delarue, Agnès Buzyn, Bruno Varet, Wolf H. Fridman, Véronique Frémeaux-Bacchi, Olivier Hermine
Journal: Blood (2007)
DNA Double Strand Breaks Induction by Zalypsis, a Novel Marine Compound, Results in Potent Antimyeloma Activity
Authors: Enrique M Ocio, Patricia Maiso, Xi Chen, Mercedes Garayoa, Stela Álvarez-Fernández, Laura San-Segundo, David Vilanova, Lucía López-Corral, Juan Carlos Montero, Teresa Hernández-Iglesias, Enrique de Álava, Carlos Galmarini, Pablo Avilés, Carmen Cuevas, Atanasio Pandiella, J.F. San Miguel
Journal: Blood (2008)